Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole

Journal of Clinical Oncology

Volumn 26, Issue 34, 2008, Pages 5569-5575

  Viale, Giuseppe ^a   Giobbie Hurder, Anita ^b   Regan, Meredith M ^b   Coates, Alan S ^b   Mastropasqua, Mauro G ^b   Dell'Orto, Patrizia ^b   Maiorano, Eugenio ^b   MacGrogan, Gaëtan ^b   Braye, Stephen G ^b   Öhlschlegel, Christian ^b   Neven, Patrick ^b   Orosz, Zsolt ^b   Olszewski, Wojciech P ^b   Knox, Fiona ^b   Thürlimann, Beat ^b   Price, Karen N ^b   Castiglione Gertsch, Monica ^b   Gelber, Richard D ^b   Gusterson, Barry A ^b   Goldhirsch, Aron ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; ENDOCRINE SYSTEM; FEMALE; HUMANS; KI-67 ANTIGEN; NITRILES; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TAMOXIFEN; TRIAZOLES;

EID: 57149103724     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.0829     Document Type: Article

References (30)

1. Goldhirsch A, Wood WC, Gelber RD, et al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144, 2007
2. Clahsen PC, Van de Velde CJ, Duval C, et al: The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 25:356-363, 1999
3. Gerdes J, Schwab U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983
4. Lehr HA, Hansen DA, Kussick S, et al: Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol 30:1314-1320, 1999
5. Thor AD, Liu S, Moore DH, et al: Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17:470-477, 1999
6. Sahin AA, Ro J, Ro JY, et al: Ki-67 immunostaining in node-negative stage I/II breast carcinoma: Significant correlation with prognosis. Cancer 68:549-557, 1991
7. Domagala W, Markiewski M, Harezga B, et al: Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein. Clin Cancer Res 2:147-154, 1996
8. Pietiläinen T, Lipponen P, Aaltomaa S, et al: The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122:687-692, 1996
9. Trihia H, Murray S, Price K, et al: Ki-67 expression in breast carcinoma. Cancer 97:1321-1331, 2003
10. Jansen RL, Hupperets PS, Arends JW, et al: MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460-465, 1998
11. de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12 155 patients. Br J Cancer 96:1504-1513, 2007
12. Chang J, Ormerod M, Powles TJ, et al: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89:2145-2152, 2000
13. Archer CD, Parton M, Smith IE, et al: Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89:1035-1041, 2003
14. Miller WR, White S, Dixon JM, et al: Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 94:1051-1056, 2006
15. Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170, 2007
16. Viale G, Regan MM, Mastropasqua MG, et al: Predictive value of tumor Ki-67 in two randomized trials of adjuvant chemo-endocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207-212, 2008
17. Thürlimann B, Keshaviah A, Coates AS, et al: BIG 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
18. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007
19. Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571-1581, 2006
20. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al: Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9:23-28, 2008
21. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
23. Cox DR: Regression models and life tables (with discussion). J Roy Stat Soc B 34:187-220, 1972
24. Bonetti M, Gelber RD: A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19: 2595-2609, 2000
25. Pinto AE, Andre S, Laranjeira C, et al: Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology 37:45-50, 2005
26. Lewis-Wambi JS, Jordan VC: Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis 24: 93-105, 2005
27. Osborne CK, Shou J, Massarweh S, et al: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s-8870, 2005
28. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002
29. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
30. Kaufmann M, Jonat W, Hilfrich J, et al: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. J Clin Oncol 25:2664-2670, 2007